BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...in April, and now has a market cap of W212 billion ($180.6 million). In August, SillaJen Inc....
...trial to treat hepatocellular carcinoma. The company’s stock has since dropped an additional 55%, giving SillaJen...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...active applications to list on STAR (see "Chipscreen Sets High Standard in Shanghai Debut" ). SillaJen Inc....
...a Phase III trial to treat liver cancer. Pexa-Vec is SillaJen's only clinical product (see "Sillajen...
BioCentury | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

...company Western Oncolytics LLC (Pittsburgh, Penn.) hired Helena Chaye as CEO. She was CBO of SillaJen Inc....
BioCentury | Aug 2, 2019
Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

...The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest...
...about the modality as a whole than about the virus' specific construct and trial design. SillaJen Inc....
...the trial wasn't successful and whether it will continue with other ongoing trials of Pexa-Vec. SillaJen...
BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...gained exclusive China rights to it in 2009 from Jennerex Inc., which was acquired by SillaJen Inc....
...The Chinese University of Hong Kong Corporate partners: Lee’s Pharmaceutical Holdings Ltd., Sorrento Therapeutics Inc., SillaJen Inc....
...Lee’s Pharmaceutical Holdings Ltd. (HKSE:950), Hong Kong, China Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. SillaJen Inc....
BioCentury | Jul 12, 2018
Product R&D

All-in-one viruses

...Archinard told BioCentury. However, a 2015 paper in Molecular Therapy from researchers at Transgene’s partner SillaJen Inc....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. PsiOxus Therapeutics Ltd., Abingdon, U.K. Replimune Group Inc., Woburn, Mass. SillaJen Inc....
BioCentury | Jan 26, 2018
Company News

SillaJen, ABL expand deal to ready vaccine for clinic

...ABL is manufacturing Pexa-Vac. The company expects to bring JX-970 into clinical trials next half. SillaJen...
...and vaccinia growth factor. SillaJen Inc. (KOSDAQ:215600), Busan, South Korea Institut Mérieux, Lyon, France Business: Cancer Jennie Walters SillaJen ABL JX-970...
BioCentury | Aug 18, 2017
Company News

SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

...in an "early phase clinical trial" to treat advanced colorectal cancer. NCI will manage and SillaJen...
...GM-CSF and deletion of thymidine kinase). NCI said trial dates have not yet been set. SillaJen...
...not respond to inquiries. Pexa-Vec is in Phase III testing to treat hepatocellular carcinoma (HCC). SillaJen Inc....
BioCentury | Aug 18, 2017
Clinical News

Transgene starts Phase I/IIa of Pexa-Vec plus Opdivo for HCC

...endpoints include disease control rate (DCR) and overall survival (OS). Transgene has exclusive rights from SillaJen Inc....
...Pexa-Vec is a recombinant vaccinia virus (addition of GM-CSF and deletion of thymidine kinase). SillaJen Inc....
...control rate (DCR) and overall survival (OS) Status: Phase I/IIa started Milestone: NA Jaime De Leon JX-594 Pexa-Vec pexastimogene devacirepvec TG6006 SillaJen Inc. Transgene...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...Among the largest gainers was SillaJen Inc. , which made its KOSDAQ debut in late 2016. SillaJen...
...Ib trial of Pexa-Vec combined with Regeneron’s anti-PD-1 mAb REGN2810 to treat renal cell carcinoma. SillaJen...
...Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. SillaJen Inc....
Items per page:
1 - 10 of 31
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...in April, and now has a market cap of W212 billion ($180.6 million). In August, SillaJen Inc....
...trial to treat hepatocellular carcinoma. The company’s stock has since dropped an additional 55%, giving SillaJen...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...active applications to list on STAR (see "Chipscreen Sets High Standard in Shanghai Debut" ). SillaJen Inc....
...a Phase III trial to treat liver cancer. Pexa-Vec is SillaJen's only clinical product (see "Sillajen...
BioCentury | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

...company Western Oncolytics LLC (Pittsburgh, Penn.) hired Helena Chaye as CEO. She was CBO of SillaJen Inc....
BioCentury | Aug 2, 2019
Clinical News

SillaJen, Transgene fall with latest oncolytic virus setback

...The failure of Pexa-Vec from Transgene and SillaJen in a Phase III study is the latest...
...about the modality as a whole than about the virus' specific construct and trial design. SillaJen Inc....
...the trial wasn't successful and whether it will continue with other ongoing trials of Pexa-Vec. SillaJen...
BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...gained exclusive China rights to it in 2009 from Jennerex Inc., which was acquired by SillaJen Inc....
...The Chinese University of Hong Kong Corporate partners: Lee’s Pharmaceutical Holdings Ltd., Sorrento Therapeutics Inc., SillaJen Inc....
...Lee’s Pharmaceutical Holdings Ltd. (HKSE:950), Hong Kong, China Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. SillaJen Inc....
BioCentury | Jul 12, 2018
Product R&D

All-in-one viruses

...Archinard told BioCentury. However, a 2015 paper in Molecular Therapy from researchers at Transgene’s partner SillaJen Inc....
...Co. Inc. (NYSE:MRK), Kenilworth, N.J. PsiOxus Therapeutics Ltd., Abingdon, U.K. Replimune Group Inc., Woburn, Mass. SillaJen Inc....
BioCentury | Jan 26, 2018
Company News

SillaJen, ABL expand deal to ready vaccine for clinic

...ABL is manufacturing Pexa-Vac. The company expects to bring JX-970 into clinical trials next half. SillaJen...
...and vaccinia growth factor. SillaJen Inc. (KOSDAQ:215600), Busan, South Korea Institut Mérieux, Lyon, France Business: Cancer Jennie Walters SillaJen ABL JX-970...
BioCentury | Aug 18, 2017
Company News

SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

...in an "early phase clinical trial" to treat advanced colorectal cancer. NCI will manage and SillaJen...
...GM-CSF and deletion of thymidine kinase). NCI said trial dates have not yet been set. SillaJen...
...not respond to inquiries. Pexa-Vec is in Phase III testing to treat hepatocellular carcinoma (HCC). SillaJen Inc....
BioCentury | Aug 18, 2017
Clinical News

Transgene starts Phase I/IIa of Pexa-Vec plus Opdivo for HCC

...endpoints include disease control rate (DCR) and overall survival (OS). Transgene has exclusive rights from SillaJen Inc....
...Pexa-Vec is a recombinant vaccinia virus (addition of GM-CSF and deletion of thymidine kinase). SillaJen Inc....
...control rate (DCR) and overall survival (OS) Status: Phase I/IIa started Milestone: NA Jaime De Leon JX-594 Pexa-Vec pexastimogene devacirepvec TG6006 SillaJen Inc. Transgene...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...Among the largest gainers was SillaJen Inc. , which made its KOSDAQ debut in late 2016. SillaJen...
...Ib trial of Pexa-Vec combined with Regeneron’s anti-PD-1 mAb REGN2810 to treat renal cell carcinoma. SillaJen...
...Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. SillaJen Inc....
Items per page:
1 - 10 of 31